This is multicentre, open-label, randomized, phase II trial in patients with locally advanced
or metastatic pancreatic cancer. Subjects will be randomized in a 1:1 ratio to receive
gemcitabine/cisplatin in combination with Sorafenib (arm A) or gemcitabine/cisplatin alone
(arm B), as first-line chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Collaborator:
Mario Negri Institute for Pharmacological Research